688289.SS Stock Analysis
68
Avoid
Based on Eyestock quantitative analysis, 688289.SS`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
Sansure Biotech, Inc. engages in the research, development, production, and sales of diagnostic reagents and instruments. The company is headquartered in Changsha, Hunan and currently employs 1,729 full-time employees. The company went IPO on 2020-08-28. The firm's diagnostic reagent products are comprised of viral hepatitis series, reproductive tract infection and genetic series, pediatric infection series and nucleic acid blood screening series. The instrument products include automatic nucleic acid detection reaction system construction series and fluorescent polymerase chain reaction (PCR) monitoring and analysis software. The firm also provides related inspection services, including medical inspection and scientific research services which are provided for medical institutions.